Related by context. All words. (Click for frequent words.) 74 pharmacodynamic PD 72 pharmacokinetics PK 71 pharmacokinetic 71 pharmacokinetics 71 pharmacokinetic profile 70 viral kinetics 70 tolerability 70 pharmacodynamic effects 70 pharmacokinetic PK 68 PXD# 68 Pharmacokinetic 68 anti leukemic 67 favorable pharmacokinetic profile 67 safety tolerability pharmacokinetic 67 pharmacodynamics PD 67 pharmacokinetic parameters 67 pharmacokinetics pharmacodynamics 66 antiviral efficacy 66 analgesic efficacy 66 GFT# 66 pharmacodynamic endpoints 66 fosbretabulin 65 ascending dose 65 tanespimycin 65 secondary efficacy endpoints 65 pharmacodynamics 65 Traficet EN 65 pharmacodynamic profile 65 tolerability profile 65 safety tolerability 65 safety tolerability pharmacokinetics 65 imetelstat 65 pharmacodynamic properties 65 antitumor activity 64 pharmacokinetic profiles 64 dose limiting toxicities 64 dose proportionality 64 GAMMAGARD 64 preclinical efficacy 64 GSK# [001] 64 pharmacokinetic pharmacodynamic 64 pharmacokinetic PK profile 64 ganetespib 64 dose cohorts 64 CK # 64 ascending doses 64 GRN#L 64 PS# [001] 64 biodistribution 64 posaconazole 64 CYT# 64 pharmacokinetic characteristics 64 antiviral activity 64 ENMD # 64 pharmacodynamic parameters 64 preclinically 64 efficacy endpoints 64 varespladib 63 teriflunomide 63 peripheral blood mononuclear 63 SCH # 63 INCB# [001] 63 plasma pharmacokinetics 63 cannabinor 63 riociguat 63 urate lowering 63 secondary endpoints 63 OXi# 63 RDEA# 63 Azedra 63 pharmacologic 63 HGS ETR1 63 NGX# 63 nonclinical studies 63 Phase 2a trial 63 mg kg dose 63 pomalidomide 63 elotuzumab 63 Pharmacodynamic 63 Pharmacokinetic PK 63 phase Ib 63 selective modulator 63 Apoptone 63 viral kinetic 63 Secondary efficacy endpoints 63 efficacy tolerability 63 Secondary endpoints 63 antitumor effect 63 GLYX 63 Omacetaxine mepesuccinate 62 nab paclitaxel 62 desvenlafaxine succinate 62 tolerability profiles 62 tolerability pharmacokinetics 62 PRT# 62 plasma renin activity 62 Bezielle 62 CA4P 62 XL# [003] 62 Phase 1b 62 APOPTONE 62 pharmacokinetic studies 62 QTc prolongation 62 prospectively defined 62 PEG Interferon lambda 62 surrogate endpoint 62 vidofludimus 62 solithromycin 62 INCB# [002] 62 erythropoietic 62 clinically meaningful 62 APTIVUS r 62 galiximab 62 anti angiogenic 62 noninferiority 62 glucose lowering 62 eculizumab 62 Phase Ib 62 CANCIDAS 62 achieved statistical significance 62 DLTs 62 TRIOLEX 62 obatoclax 62 Sym# 62 subcutaneously administered 61 systemically administered 61 CIMZIA TM 61 antiangiogenic 61 HCD# [002] 61 MAP# 61 mTOR inhibitors 61 ISIS # 61 DAVANAT 61 prucalopride 61 CCX# 61 HGS ETR2 61 HCV SPRINT 61 Phase Ib study 61 delafloxacin 61 avosentan 61 dosing regimens 61 evaluable 61 bendamustine 61 PRTX 61 oral prodrug 61 ORMD 61 efficacy 61 HspE7 61 Doxil ® 61 IMGN# 61 TOLAMBA 61 Virulizin ® 61 RG# [001] 61 velafermin 61 mg/m2 dose 61 tolerated dose MTD 61 plasma concentrations 61 Imprime PGG 61 antitumor 61 immunogenicity 61 Chemophase 61 metabolic parameters 61 decitabine 61 antithrombotic 61 Phase 1a 61 pertuzumab 61 dose cohort 61 crizotinib PF # 61 enzastaurin 61 xenograft models 61 LymphoStat B 61 antidepressant efficacy 61 seliciclib 61 imatinib therapy 61 vivo 61 PEG SN# 61 vitro cytotoxicity 61 heavily pretreated 61 omecamtiv mecarbil 61 PEGylated interferon beta 1a 61 relapsed MM 61 clinically relevant 61 inhibitor RG# 61 alvespimycin 61 Triolex 61 arbaclofen 61 anticancer activity 60 administered subcutaneously 60 SRT# [003] 60 MAGE A3 ASCI 60 nonrandomized 60 ALB # 60 bronchodilation 60 XmAb# 60 apremilast 60 antiangiogenic therapy 60 MGd 60 Pharmacokinetic parameters 60 ritonavir boosted 60 masitinib 60 ataluren 60 angiographic outcomes 60 potent antiviral 60 KRAS status 60 radezolid 60 mcg dose 60 PK PD 60 antipsychotic efficacy 60 phase IIa clinical 60 PSN# [002] 60 AST ALT 60 S/GSK# 60 CR# vcMMAE 60 #ME# 60 R#/MEM # 60 Phenoptin 60 subcutaneous SC 60 subgroup analyzes 60 coadministration 60 recurrent glioblastoma multiforme 60 Androxal TM 60 Phase IIa trial 60 serum cortisol 60 oral FTY# 60 Symadex 60 Carfilzomib 60 PEG PAL 60 #mg dose [001] 60 NATRECOR ® 60 Pharmacokinetics PK 60 Aclidinium 60 PRECiSE 60 immunomodulation 60 cardioprotective effects 60 AEGR 60 cytoprotective 60 efficacy endpoint 60 incretin 60 pharmacodynamic markers 60 prespecified 60 ATACAND 60 rNAPc2 60 bosentan 60 Primary endpoints 60 lintuzumab 60 blinded randomized placebo controlled 60 ZD# [001] 60 genotypic resistance 60 TMC# [002] 60 rHuPH# 60 effector function 60 IFN α 60 CCR2 60 clinical endpoints 59 multiple ascending dose 59 serum antibody 59 dosage regimens 59 ofatumumab 59 hA# 59 GRNCM1 59 IFN alpha 59 lipid parameters 59 insulin detemir 59 oral bioavailability 59 torezolid phosphate 59 Phase IIa clinical 59 CIMZIA ™ 59 cilengitide 59 atacicept 59 Blinatumomab 59 dosing cohort 59 PF # [001] 59 linear pharmacokinetics 59 CORT # 59 INCB# [003] 59 alpha 2a 59 ON #.Na 59 MGCD# [001] 59 Phase 2b study 59 elagolix 59 pharmacodynamic profiles 59 TNFalpha 59 farletuzumab 59 urocortin 2 59 Ophena TM 59 immune modulating 59 HMG CoA reductase inhibitors 59 Zemiva 59 Locteron 59 antiangiogenic activity 59 serum concentrations 59 demonstrated antitumor activity 59 GMX# 59 SABCS 59 Golimumab 59 interferon IFN 59 immunomodulatory effects 59 inhaled iloprost 59 Secondary endpoints include 59 Forodesine HCl 59 neratinib 59 teduglutide 59 Phase IIa 59 Phase 1b trial 59 metaglidasen 59 HIV HCV coinfected 59 #mg BID [003] 59 CDK inhibitor 59 Tolerability 59 anti fibrotic 59 K ras mutations 59 KRN# 59 orally bioavailable 59 Debio 59 SNT MC# 59 dacetuzumab 59 Actilon 59 immunomodulating 59 NP2 Enkephalin 59 pharmacokinetic properties 59 mg dose 59 JAK inhibitor 59 active comparator 59 HCV protease 59 ILLUMINATE 59 tigecycline 59 intravesical 59 RGB # 59 PREZISTA r 59 azacitidine 59 registrational 59 mapatumumab 59 Panzem R NCD 59 Xanafide 59 cytotoxicity 59 favorable pharmacokinetic 59 HuMax EGFr 59 XL# inhibits 59 ramelteon 59 radiolabeled 59 DermaVir Patch 59 endothelin antagonists 59 pharmacokinetic interactions 59 dose escalation 59 anti arrhythmic 59 PEG IFN 59 retaspimycin 59 Capesaris 59 CoFactor 59 Enzastaurin 59 davunetide intranasal AL 59 CaPre TM 59 BCX# 59 milatuzumab 59 brivaracetam 59 Cmax 59 Preclinical studies 59 C1 INH 59 genotypic 59 primary efficacy endpoint 59 mecamylamine 59 Solid Tumors 59 eltrombopag 59 HER2 expression 59 MERLIN TIMI 59 melphalan prednisone 59 neuroregenerative 59 dosed orally 59 antitumour activity 59 BAY #-# 59 novel VDA molecule 59 olmesartan 58 depsipeptide 58 ularitide 58 HuMax CD# 58 BMS# 58 tasimelteon 58 CRLX# 58 multicentre randomized 58 tipranavir 58 myeloproliferative diseases 58 nitazoxanide 58 Teriflunomide 58 mg kg BID 58 Pharmacokinetic studies 58 antiarrhythmic 58 Aurora kinase 58 TRV# [001] 58 antifibrotic 58 renal toxicity 58 vivo efficacy 58 SYNTAX trial 58 Tyrima 58 potent antitumor 58 placebo controlled Phase 58 immunomodulatory 58 BAL# [002] 58 antitumor effects 58 maximally tolerated dose 58 rFIXFc 58 primary hypercholesterolemia 58 vWF 58 polycythemia vera PV 58 sunitinib 58 ADX# 58 aclidinium 58 QLT# 58 romidepsin 58 axitinib 58 Serdaxin 58 partial agonist 58 CIMZIA TM certolizumab pegol 58 QTc 58 JAK2 inhibitors 58 immunomodulator 58 serum urate 58 preclinical pharmacokinetic 58 fluticasone furoate 58 FOLPI 58 YONDELIS 58 inhibitory effects 58 FDG PET 58 NOX E# 58 pharmacokinetic equivalence 58 CLORETAZINE TM VNP#M 58 safinamide 58 thorough QT 58 pro apoptotic 58 low dose cytarabine 58 receptor antagonists 58 primary efficacy endpoints 58 hematological parameters 58 BNC# 58 Azixa 58 liver histology 58 placebo controlled dose escalation 58 favorable tolerability 58 immunological responses 58 bavituximab 58 secondary endpoint 58 IL 1ß 58 LEVADEX 58 5 HT2A 58 Amigal 58 custirsen 58 anti amnesic 58 Vectibix monotherapy 58 vicriviroc 58 anti proliferative 58 etanercept 58 forodesine 58 cynomolgus monkeys 58 nucleoside analog 58 iloprost 58 otelixizumab 58 antiviral potency 58 tocilizumab 58 HIV RNA 58 endothelin receptor antagonists 58 receptor inhibitor 58 pharmacological 58 RE LY ® 58 virologic response 58 non inferiority 58 Lp PLA2 58 potent antiproliferative 58 eniluracil 58 Trofex 58 ARRY 58 torsemide ER 58 Pegasys ® 58 Antiviral Activity 58 μg dose 58 bevirimat 58 ALN TTR# 58 taxane resistant 58 lacosamide 58 Posiphen 58 sapacitabine 58 HepG2 cells 58 TACI Ig 58 glatiramer acetate 58 erlotinib Tarceva ® 58 baminercept 58 cariprazine 58 AZD# 58 alagebrium 58 potent anti angiogenic 58 pitavastatin 58 AP# [003] 58 rhEPO 58 irbesartan 58 ponatinib 58 Archexin 58 MetMAb 58 dexpramipexole 58 mGluR5 NAM 58 preclinical studies 58 docetaxel chemotherapy 58 histologies 58 transgene expression 58 L PPDS 58 adecatumumab 58 evaluable patients 58 mRNA expression 58 orally administered inhibitor 58 lipid lowering therapies 58 tezampanel 58 multicenter Phase II 58 6R BH4 58 certolizumab 58 JAK inhibitors 58 catheter occlusion 58 mRCC 58 EpCAM 58 BRIM2 58 Pharmacokinetics 58 limiting toxicity 58 inflammatory biomarkers 58 antitumour 58 tumorigenicity 58 trodusquemine 58 neoadjuvant 58 Pharmacodynamics 58 RECIST Response Evaluation Criteria 58 sorafenib Nexavar 58 intravenous dosing 58 eprotirome 58 preclinical 58 Valortim 58 pharmacokinetic PK study 58 microglial activation 58 bortezomib 58 Synavive 58 IIIa inhibitor 58 pegylated interferon alfa 2b 58 phase IIb clinical 58 Bicifadine 58 antiapoptotic 58 chemosensitivity 58 ZYBRESTAT 58 fibrinolytic 58 APPRAISE 58 Plicera 58 Trastuzumab 58 intracoronary 58 orally dosed 58 HuMax CD4 58 receptor agonists 58 ADAS Cog 57 IDX# 57 vascular disrupting agent 57 ALN TTR 57 fulvestrant 57 TG# [003] 57 Valortim R 57 neuroprotective properties 57 antiangiogenic agents 57 telbivudine 57 EOquin 57 Phase Ib II 57 exploratory endpoints 57 virologic 57 double blinded placebo 57 caspofungin 57 CINQUIL 57 calcineurin inhibitors 57 dyskinesia PD LID 57 MEND CABG 57 NPH insulin 57 HER3 57 DDP# 57 VEGF receptor 57 ZYBRESTAT fosbretabulin 57 EGFR HER2 57 alefacept 57 Dacogen injection 57 neuroprotective 57 virologic responses 57 Phase 1a clinical 57 LY# [003] 57 OncoVEX GM CSF 57 Phase Ib clinical 57 liposomal formulation 57 antiretroviral naive 57 Targretin 57 potent inhibition 57 mitogenic 57 synthetic retinoid 57 renal function 57 HIF PHI 57 ELACYT 57 histone deacetylase HDAC inhibitor 57 florbetaben 57 antidiabetic 57 PKC# 57 lesinurad 57 ALGRX 57 null responder 57 paricalcitol 57 LY# [002] 57 retinal thickness 57 tecarfarin 57 nephrotoxicity 57 platelet reactivity 57 IFN beta 57 EOquin TM 57 pressor response 57 microtubule targeting 57 mg TID 57 tumor xenograft models 57 AZX# 57 demonstrated statistically significant 57 busulfan 57 PRX # 57 potent inhibitor 57 placebo controlled 57 phase IIb 57 NLX P# 57 endoscopic remission 57 celgosivir 57 β blockers 57 adalimumab 57 OMP #M# 57 PEGPH# 57 Gag polymorphisms 57 aminotransferase levels 57 secretory phospholipase A2 sPLA2 57 piperacillin tazobactam 57 Vilazodone 57 monotherapy 57 demonstrated clinically meaningful 57 radiation dosimetry 57 nalbuphine ER 57 single ascending dose 57 AZILECT R 57 CTAP# Capsules 57 peginesatide 57 Lp PLA 2 57 Omacetaxine 57 LT NS# 57 lumiliximab 57 BEXXAR Therapeutic Regimen 57 diabetic neuropathic pain 57 LHRH antagonists 57 airway hyperresponsiveness 57 Pemetrexed 57 Initiated Phase 57 VEGFR2 57 TLK# 57 receptor subtypes 57 fluvastatin 57 APTIVUS 57 VAPRISOL 57 STRIDE PD 57 potent antitumor activity 57 flavopiridol 57 treatment naive genotype 57 dexamethasone Decadron 57 SAR# [004] 57 primary endpoints 57 primary endpoint 57 Kahalalide F 57 urinary N telopeptide 57 Epanova 57 ADAGIO study 57 bicifadine 57 Phase 2a 57 MEND CABG II 57 cobiprostone 57 Phase #b/#a trial 57 liver transaminases 57 antitumor efficacy 57 Valortim ® 57 phase IIa 57 selective agonist 57 INC# 57 INGN 57 ORENCIA ® 57 alvimopan 57 Bendavia 57 mycophenolate mofetil 57 dimebon 57 HCV RESPOND 2 57 airway responsiveness 57 CEQ# 57 huC# DM4 57 HuLuc# 57 relapsing multiple sclerosis 57 Phase IIB 57 Exelixis compounds 57 mg BID 57 evaluable subjects 57 subanalysis 57 dose escalation trial 57 vivo potency 57 Neuradiab 57 isatoribine 57 glufosfamide 57 humanized anti 57 CG# [003] 57 vascular disrupting agents 57 ISTODAX 57 EURIDIS 57 ug kg 57 ancrod 57 ranolazine 57 prospective multicentre 57 icatibant 57 refractory CLL 57 clomipramine 57 Cloretazine 57 rFVIIa 57 Zerenex 57 uric acid lowering 57 proteasome inhibitor 57 Anticalins ® 57 peginterferon alfa 2b 57 QT QTc 57 PCK# 57 imatinib resistant 57 PD LID 57 DAPT 57 ISENTRESS 57 subcutaneous formulation 57 IL#B 57 sorafenib Nexavar ® 57 thymalfasin 57 Cethromycin 57 follicular NHL 57 peripherally acting 57 refractory AML 57 clinically meaningful improvements 57 trabectedin 57 rhIGFBP 3 57 EGFR mutations 57 PSMA ADC 57 insulin sensitizing 57 NNRTI resistance 57 MP4OX 57 factor TNF 57 lanthanum carbonate 57 sustained virologic response 57 Seliciclib 57 relapsed MCL 57 ritonavir boosting 57 CGEN # 57 radiolabeled monoclonal antibody 57 aplindore 57 HCV replicon 57 VP# [004] 57 rBChE 57 novel histone deacetylase 57 HIF PH inhibitors 57 GHRH 57 dose regimens 57 Aptivus ® 57 Secondary endpoints included 57 lenalidomide dexamethasone 57 ALKS 57 ACTEMRA TM 57 Dasatinib 57 tolvaptan 57 MIRCERA 57 receptor tyrosine kinase inhibitor 57 eszopiclone 56 histone deacetylase inhibitor 56 TLR7 56 perifosine 56 liposomal doxorubicin 56 gemcitabine carboplatin 56 Phase 2b clinical 56 MORAb 56 PBMCs 56 Efficacy 56 elevated creatinine 56 Panzem R 56 RAV# 56 Hsp# inhibitors 56 annexin 56 vitro experiments 56 secondary efficacy endpoint 56 KRAS mutations occur 56 peginterferon 56 Ceplene/IL-2 56 neurologic progression 56 Phase 2b trial 56 NEUGENE antisense 56 insulin degludec 56 VA# [002] 56 TG# [001] 56 postprandial glucose 56 clinically meaningful differences 56 myopathy rhabdomyolysis 56 Phase Ib clinical trials 56 optimal dosing 56 TPI ASM8 56 Phase Ia 56 BENICAR HCT 56 apolipoprotein B 56 GOUT 56 dose escalation phase 56 F FDG PET 56 interferon alfa 56 blinatumomab 56 5 Fluorouracil 56 pramlintide 56 Cloretazine R VNP#M 56 ongoing Phase 1b 56 nanomolar range 56 AACR NCI EORTC 56 preclinical models 56 Multiple Ascending Dose 56 Antiangiogenic 56 visilizumab 56 serum HBV DNA 56 splenectomized patients 56 virological response 56 EGFr 56 Natalizumab 56 Ostarine 56 AVADO 56 VELCADE melphalan 56 superficial bladder cancer 56 elesclomol 56 Tarceva TM 56 intravenously administered 56 insulin glargine 56 octreotide 56 clevidipine 56 hemagglutination inhibition HAI 56 relapsed multiple myeloma 56 O PPDS 56 RSD# oral 56 Dapagliflozin 56 DOXIL 56 miRNA expression 56 dopaminergic 56 Interferon beta 1a 56 placebo controlled studies 56 elacytarabine 56 glucose homeostasis 56 NXL# 56 regorafenib 56 sitaxsentan 56 prospective randomized controlled 56 CXB# 56 GAP #B# 56 huN# DM1 56 CCyR 56 somatostatin 56 predictive biomarker 56 timepoints 56 CBLB# 56 immunologic 56 Aplidin R 56 CYT# potent vascular disrupting 56 multicenter randomized controlled 56 Phase 2a clinical 56 seroprotection 56 valsartan 56 selective kinase inhibitor 56 Pimavanserin 56 #mg/day [002] 56 Multimeric 56 TRO# 56 HCV genotypes 56 combinability 56 veltuzumab 56 glomerular filtration 56 QD dosing 56 sitagliptin 56 Aflibercept 56 vascular disrupting 56 dyslipidaemia 56 serum lipid 56 standard chemotherapy regimen 56 etoposide 56 interleukin IL -# 56 R#/MEM 56 Hematologic toxicity 56 Response Evaluation Criteria 56 p# biomarkers 56 antiproliferative effects 56 hypercalcemia 56 NMDA antagonists 56 tirofiban 56 TELCYTA 56 phenotypic 56 Altastaph 56 fosamprenavir 56 interferon gamma 1b 56 antibody responses 56 canakinumab 56 PREVENT IV 56 ADCS CGIC 56 placebo controlled clinical trials 56 Hyphanox 56 plasma kallikrein inhibitor 56 vasodilatory 56 patients evaluable 56 REMINYL ® 56 ToGA 56 BIBW 56 Scale PANSS 56 EGFR tyrosine kinase inhibitors 56 serum phosphorous 56 Tarvacin TM 56 serotonergic 56 prognostic significance 56 AEZS 56 triphendiol 56 ICA # 56 serum phosphate 56 daily subcutaneous injections 56 composite endpoint 56 DP b# 56 linaclotide 56 randomized Phase III 56 ARB telmisartan 56 guanfacine extended release 56 candesartan cilexetil 56 uricase 56 trastuzumab Herceptin R 56 ACE inhibitor ramipril 56 double blinded randomized 56 TMC# C# 56 cMET 56 Preclinical 56 abciximab 56 ADCS ADL 56 Vidaza azacitidine 56 sustained virological response 56 motesanib diphosphate 56 rindopepimut 56 protease inhibitor PI 56 ribavirin RBV 56 PTHrP 56 intermittent dosing 56 Taxotere ® 56 JVRS 56 Preclinical studies suggest 56 mg/m2 cohort 56 potency selectivity 56 selective inhibition 56 DCCR 56 alkylating agent 56 circulating EPCs 56 DACH platinum 56 Vitaxin 56 REG1 56 chlorambucil 56 Interferon alpha 56 bleomycin 56 lisdexamfetamine dimesylate 56 immunoregulatory 56 HyQ 56 immunoreactivity 56 Tasimelteon 56 CRESTOR #mg 56 antibody titers 56 tipranavir r 56 pegylated liposomal doxorubicin 56 lactate dehydrogenase LDH 56 dosing cohorts 56 HGS# 56 plus ribavirin 56 evaluating tivozanib 56 Clolar ® 56 HERmark 56 BiTE 56 multitargeted 56 triglyceride lowering 56 BrachySil TM 56 pheochromocytoma 56 Homspera 56 follicular lymphomas 56 bortezomib Velcade 56 limiting toxicity DLT 56 statistically significant p = 56 hepatotoxicity 56 Pharmacological 56 kinase inhibitor 56 Phase #/#a 56 EndoTAGTM 1 56 Sapacitabine 56 omega interferon 56 tapentadol ER 56 MLN# 56 tyrosine phosphorylation 56 oral rivaroxaban 56 Phase IIIb clinical 56 febuxostat 56 edoxaban 56 elevated ALT 56 cardiac toxicity 56 bronchodilatory 56 CRx 56 subcutaneous PRO